BioMarin's Voxzogo Meets Goal in Late-Stage Study for Hypochondroplasia
BMRN's shares rise after Voxzogo hits the main goal in a late-stage hypochondroplasia study, supporting planned FDA filings in 2026.
BMRN - BioMarin Pharmaceutical Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$89.93
DETAILS
HIGH:
$120.00
LOW:
$50.00
MEDIAN:
$95.00
CONSENSUS:
$89.93
UPSIDE:
66.26%
Stock News
BioMarin Reveals Dwarfism Study Data, Stock Soars
BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) stock is trading higher on Thursday as the company is celebrating positive results from its Phase 3 CANOPY-HCH-3 study for VOXZOGO (vosoritide) in children with hypochondroplasia.
BioMarin's drug shows significant growth gains in children in late-stage trial
BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that leads to short stature helped boost growth in children, meeting the main goal of a late-stage study and sending shares up nearly 5% in extended trading.
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline) of 2.33 cm/yr compared to placebo at week 52, as well as statistically significant increases in standing height and height Z-score Study demonstrated statistically significant improvement in arm span at week 52 compared to placebo, a key measure linked to functional independence Safety findings consistent with the established profile in achondroplasia with no new safety signals identified Supplemental New Drug Application (sNDA) submission to U.S. Food and Drug Administration (FDA) planned for third quarter, followed by submissions to the European Medicines Agency (EMA) and other regional health authorities Full data to be presented at an upcoming medical meeting SAN RAFAEL, Calif., May 20, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 CANOPY-HCH-3 study evaluating treatment with VOXZOGO ® (vosoritide) in children with hypochondroplasia met its primary endpoint, demonstrating a statistically significant increase in the change from baseline at week 52 in annualized growth velocity (AGV) compared to placebo (LS mean difference +2.33 cm/yr, p
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study
BioMarin shares fall after BMN 401 meets a biomarker goal but misses a key radiographic endpoint in a late-stage ENPP1 deficiency study.
Here Are Tuesday’s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More
Pre-Market Stock Futures: Futures are trading lower on Tuesday as the sell-off in technology stocks carried through to Monday and is headed down that road today. All of the major indices, except the Dow Jones Industrial Average, which closed 0.32% higher at 49,668, finished the day lower. The small-cap Russell 2000 was the big loser... Here Are Tuesday's Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More
BioMarin's genetic disease therapy shows mixed results in late-stage study
BioMarin Pharmaceutical said on Monday its experimental treatment for a rare genetic condition met one of the two main goals in a late-stage study.
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration, one of the study's co-primary endpoints; however, no improvement was observed in Radiographic Global Impression of Change (RGI-C) scores, the study's other co-primary endpoint and an important clinical measure of change in rickets severity Company is evaluating data to determine next steps SAN RAFAEL, Calif., May 18, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced results from the pivotal Phase 3 ENERGY 3 trial evaluating BMN 401 in children aged 1-12 with ENPP1 deficiency, a rare, serious and progressive genetic condition.
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as reports indicate that President Trump declined Iran's counteroffer for peace. This comes after a remarkable Friday, when stocks roared to record highs, driven primarily by a stronger-than-expected April jobs report that eased economic concerns and by a... Here Are Monday's Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy's, and More
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition
BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions, and robust revenue guidance. BMRN's acquisition of Amicus Therapeutics adds GALAFOLD and POMBILITI + OPFOLDA, boosting 2026 revenue guidance to $3.825–$3.925 billion and targeting 20% YoY growth. VOXZOGO expansion into hypochondroplasia and ongoing clinical trials represent major catalysts, with topline Phase 3 data expected in Q2 2026.
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, while new Amicus deal lifts the 2026 outlook.
BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript
Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.13 per share a year ago.
BioMarin Reports First Quarter 2026 Financial and Operating Results
First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growth Rate of 20% Y/Y at the Midpoint, and Reflecting the Addition of GALAFOLD® and POMBILITI® + OPFOLDA® to BioMarin's Portfolio Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with achondroplasia Researchers will present additional data from studies of VOXZOGO for hypochondroplasia, ahead of pivotal topline Phase 3 data expected in the first half of 2026 SAN RAFAEL, Calif., May 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new research from studies of VOXZOGO ® (vosoritide) in children with achondroplasia demonstrating positive impact on important health indicators, including arm span and bone density.
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin Completes Acquisition of Amicus Therapeutics
Acquisition Adds Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease to BioMarin's Commercial Portfolio BioMarin Expects to Provide Updated FY 2026 Guidance During its First Quarter Earnings Call, May 4, 2026 SAN RAFAEL, Calif., April 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion.
Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Advanced Micro Devices, CrowdStrike, DoorDash, Fortinet, GE Vernova, Snap, StubHub, and More
Pre-Market Stock Futures: The futures are trading lower as we get set to start a new trading week, and after last week's string of record highs, it may be tough to duplicate the stellar performance that Wall Street put on. All of the major indices closed higher, except the Dow Jones Industrials, which finished the... Here Are Monday's Top Wall Street Analyst Research Calls: Adobe, Advanced Micro Devices, CrowdStrike, DoorDash, Fortinet, GE Vernova, Snap, StubHub, and More
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
SAN RAFAEL, Calif., April 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m.
Price Targets
BioMarin price target lowered to $111 from $116 at Canaccord
$111.00
(was $54.10)
Canaccord Genuity
BioMarin price target lowered to $62 from $64 at Leerink
$62.00
(was $49.67)
Leerink Partners
BioMarin price target lowered to $50 from $55 at H.C. Wainwright
$50.00
(was $50.15)
H.C. Wainwright
BioMarin reinstated with a Neutral at Goldman Sachs
$69.00
(was $54.06)
Goldman Sachs
BioMarin price target raised to $120 from $110 at Evercore ISI
$120.00
(was $54.36)
Evercore ISI
BioMarin price target lowered to $82 from $94 at Bernstein
$82.00
(was $55.46)
William Pickering
·
Tudor Pickering
BioMarin resumed with an Overweight at Morgan Stanley
$120.00
(was $53.18)
Sean Laaman
·
Morgan Stanley
Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN): "data looks viable and is a positive sign"
$103.00
(was $59.86)
Akash Tewari
·
Jefferies
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays
$105.00
(was $59.74)
Eliana Merle
·
Barclays
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Freedom Capital Markets
$105.00
(was $60.47)
Ilya Zubkov
·
Loop Capital Markets
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $104 at Canaccord
$104.00
(was $60.26)
Whitney Ijem
·
Canaccord Genuity
BioMarin price target lowered to $95 from $98 at Oppenheimer
$95.00
(was $62.92)
Oppenheimer
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $68 at Stifel
$68.00
(was $61.44)
Paul Matteis
·
Stifel Nicolaus
BioMarin price target raised to $75 from $70 at Wells Fargo
$75.00
(was $59.95)
Wells Fargo
BioMarin price target lowered to $84 from $122 at Piper Sandler
$84.00
(was $57.15)
Piper Sandler
BioMarin upgraded to Buy from Hold at Canaccord
$98.00
(was $54.59)
Canaccord Genuity
BioMarin price target raised to $100 from $80 at Truist
$100.00
(was $59.28)
Joon Lee
·
Truist Financial
BioMarin price target raised to $60 from $55 at H.C. Wainwright
$60.00
(was $61.15)
H.C. Wainwright
BioMarin downgraded to Market Perform from Outperform at Leerink
$60.00
(was $53.89)
Leerink Partners
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered at Bernstein Amid 'Tough NT Setup'
$88.00
(was $53.57)
William Pickering
·
Tudor Pickering